VKTX
Viking Therapeutics, Inc. - Common Stock NASDAQ
Last close
$30.11
as of 21 Sep 2026
- Avg call return
- −13.7%
- −12.5% vs. index
- Scored calls
- 1
- Channels
- 1
- Win Rate
- 0%
- Side taken
- 1Buy 0Sell
1 scored calls · 1 channels · first tracked 04 Sep 2026
VKTX: tracked call record. Across the full tracked record, 1 of 1 published calls are scored, with an average call return of -13.65%. Scored calls were published from 04 Sep 2026 to 04 Sep 2026, measured from each entry price to its latest available close (price dates: 21 Sep 2026 to 21 Sep 2026). Average benchmark excess is -12.55 percentage points, based on 1 of the 1 scored calls only. Unscored calls are excluded from averages. Holding periods and price freshness vary. These are averages of directional call returns, not an investable portfolio return; fees, dividends and execution costs are not included.
Who is calling VKTX
Last 12 months · 1 buying · 0 selling
-
01
Dylan Rieger Buy Calls 1 Return −13.7% Show calls
-
04 Sep 2026
Buy
Entry
$34.87
Now
$30.11
−13.7%
vs. index
−12.5%
AI-extracted call. Cite this call
I like the size of the obesity opportunity, the strength of the pipeline, and the company's solid balance sheet. There's clearly a path to major upside here if VK2735 succeeds, but this is still a clinical stage biotech in a very competitive market, so investors need to respect that risk.
-
04 Sep 2026
Buy
Entry
$34.87
Now
$30.11
−13.7%
vs. index
−12.5%
Every video calling VKTX
Understand these figures or report an error: Methodology Corrections policy